In addition, positive effect associated with SGLT-2 inhibitors use is observed in nonalcoholic fatty liver disease (NAFLD), which is considered as a risk factor of cirrhosis and hepatocellular carcinoma [110]. Here, SLC5A2 is linked to hepatocellular carcinoma.